Medication and psychological treatment for panic disorder: A case of competition or synergy?

Current Opinion in Psychiatry

Volumn 10, Issue 2, 1997, Pages 116-120

  Perry, Anne C ^a   Drummond, Lynne M ^b,c  

^a SPRINGFIELD HOSPITAL   (United Kingdom)

^b ST GEORGE S HOSPITAL   (United Kingdom)

^c George's Hospital Medical School   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ALPRAZOLAM; BENZODIAZEPINE DERIVATIVE; BUSPIRONE; PAROXETINE; SEROTONIN UPTAKE INHIBITOR; TRICYCLIC ANTIDEPRESSANT AGENT;

AGORAPHOBIA; BEHAVIOR THERAPY; CLINICAL TRIAL; COGNITIVE THERAPY; HUMAN; META ANALYSIS; ONSET AGE; PANIC; PSYCHOTHERAPY; RELAXATION TRAINING; SHORT SURVEY;

EID: 0030994752     PISSN: 09517367     EISSN: None     Source Type: Journal    
DOI: 10.1097/00001504-199703000-00011     Document Type: Short Survey

References (35)

1. American Psychiatric Association: Diagnostic and statistical manual of mental disorders, edn 3, revised. Washington, DC: American Psychiatric Association; 1987.
2. Starcevic V, Fallon S, Uhlenhuth EH, Pathak D: Comorbidity rates do not support distinction between panic disorder and generalized anxiety disorder. Psychopathology 1994, 27:269 272.
3. Noyes R, Woodman C, Garvey MJ, Cook BL: Generalized anxiety disorder vs. panic disorder: distinguishing characteristics and patterns of comorbidity. J Nerv Ment Dis 1992, 180:369 379.
4. Telch MJ, Schmidt NB, Jaimez TLN, Jacquin KM, Harrington PJ: Impact of cognitive-behavioural treatment on quality of life in panic disorder patients. J Consult Clin Psychol 1995, 63:823 830.
5. Clark D: A cognitive approach to panic. Behav Res Ther 1986, 24:461 470.
6. Clark DM: Panic disorder: from theory to therapy. In Frontiers of cognitive therapy. Edited by Salkovskis PM. New York: Guilford Press; 1996:318 344. An excellent review of the cognitive theory of panic disorder, the experimental investigations that have been carried out to test it and responses to criticisms of the theory. An account of cognitive treatment was also given, as well as a summary of the controlled trials that have so far been carried out to test its effectiveness.
7. Peterson RA, Reiss S: Anxiety sensitivity index manual, edn 2. Worthing ton: International Diagnostic Systems; 1992.
8. Otto MW, Whittal ML: Cognitive-behavior therapy and the longitudinal course of panic disorder. Psychiatr Clin North Am 1995, 18:803 820. A clearly written review in which the authors discussed the development of panic disorder from a cognitive-behavioural perspective, described the different elements involved in CBT and then explored the factors that influence the maintenance and extension of treatment gains.
9. Bouchard S, Gauthier J, Laberge B, French D, Pelletier M-H, Godbout C: Exposure versus cognitive restructuring in the treatment of panic disorder with agoraphobia. Behav Res Ther 1996, 34:213 224.
10. Lloyd Williams S, Falbo J: Cognitive and performance-based treatments for panic attacks in people with varying degrees of agoraphobic disability. Behav Res Ther 1996, 34:253 264.
11. Gould RA, Otto MW, Pollack MH: A meta-analysis of treatment outcome for panic disorder. Clin Psychol Rev 1995, 15:819 844. A comprehensive review of 43 controlled studies carried out over 20 years, comparing the effectiveness of pharmacological, cognitive-behavioural and combined treatments. The authors concluded that, in general, CBT treatments yielded the largest effect sizes and the smallest attrition rates relative to pharmacotherapy and combined treatments and are cost effective.
12. Salkovskis PM, Clark DM, Gelder MG: Cognition-behaviour links in the persistence of panic. Behav Res Ther 1996, 34:453 458.
13. Arntz A, Vandenhout M: Psychological treatments of panic disorder without agoraphobia: cognitive therapy versus applied relaxation. Behav Res Ther 1996, 34:113 121.
14. Liebowitz MR: Antidepressants in panic disorders. Br J Psychiatry 1989, 155(suppl 6):46 52.
15. Ballenger JC, Burrows GD, DuPont RL, Lesser IM, Noyes R Jr, Pecknold JC, Rifkin A, Swinson RP: Alprazolam in panic disorder and agoraphobia: results from a multicenter trial. I. Efficacy in short-term treatment. Arch Gen Psychiatry 1988, 45:413 421.
16. Cross-National Collaborative Panic Study Second Phase Investigators: Drug treatment of panic disorder: comparative efficacy of alprazolam, imipramine and placebo. Br J Psychiatry 1992, 160:191 202.
17. Pollack MH, Smoller JW: The longitudinal course and outcome of panic disorder. Psychiatr Clin North Am 1995, 18:785 801.
18. Oehrberg S, Christiansen PE, Behnke K, Borup AL, Severin B, Soegaard J, Calberg H, Judge R, Ohrstrom JK, Manniche PM: Paroxetine in the treatment of panic disorder - a randomised, double-blind, placebo-controlled study. Br J Psychiatry 1995, 167:374 379.
19. Jobson KO, Davidson JRT, Lydiard RB, McCann UD, Pollack MH, Rosenbaum JF: D. Algorithm for the treatment of panic disorder with agoraphobia. Psychopharmacol Bull 1995, 31:483 485.
20. Geracioti TD: Venlafaxine treatment of panic disorder: a case series. J Clin Psychiatry 1995, 56:408 410.
21. Hetem L: Addition of d-fenfluramine to benzodiazepines produces a marked improvement in refractory panic disorder - a case report [Letter]. J Clin Psychopharmacol 1996, 16:77 78.
22. Katschnig H, Amering M, Stolk JM, Klerman GL, Ballenger JC, Briggs A, Buller R, Cassano G, Garvey M, Roth M, Solyom C: Long-term follow-up after a drug trial for panic disorder. Br J Psychiatry 1995, 167:487 494.
23. Lepola U, Koponen H, Leinonen E: A naturalistic 6-year follow-up study of patients with panic disorder. Acta Psychiatr Scand 1996, 93:181 183.
24. Spiegel DA, Bruce TJ, Gregg SF, Nuzzarello A: Does cognitive behavior therapy assist slow-taper alprazolam discontinuation in panic disorder? Am J Psychiatry 1994, 151:876 881.
25. Bruce TJ, Spiegel DA, Gregg SF, Nuzzarello A: Predictors of alprazolam discontinuation with and without cognitive behaviour therapy in panic disorder. Am J Psyciatry 1995, 152:1156 1160.
26. Basoglu A, Marks IM, Kilic C, Brewin CR, Swinson RP: Alprazolam and exposure for panic disorder with agoraphobia: attribution of improvement to medication predicts subsequent relapse. Br J Psychiatry 1994, 164:652 659.
27. Van Balkom AJLM, de Beurs E, Koele P, Lange A, Vandyck R: Long-term benzodiazepine use is associated with smaller treatment gain in panic disorder with agoraphobia. J Nerv Ment Dis 1996, 184:133 135.
28. Cottraux J, Note ID, Cungi C, Legeron P, Heim F, Chneiweiss L, Bernard G, Bouvard M: A controlled study of cognitive behaviour therapy with buspirone or placebo in panic disorder with agoraphobia. Br J Psychiatry 1995, 167:635 641.
29. Brown TA, Barlow DH: Long-term outcome in cognitive-behavioural treatment of panic disorder: clinical predictors and alternative strategies for assessment. J Consult Clin Psychol 1995, 63:754 765. The authors showed the fluctuating course of panic disorder by comparing 2-year outcome findings from both cross-sectional and longitudinal assessments of 63 patients. Unlike many other studies, the authors also included an account of the treatments given during the follow-up period and compared patients who sought further treatment to patients who did not.
30. Shear MK, Leon AC, Pollack MH, Rosenbaum JF, Keller MB: Pattern of placebo response in panic disorder. Psychopharmacol Bull 1995, 31:273 278.
31. Shear MK, Maser JD: Standardized assessment for panic disorder research. Arch Gen Psychiatry 1994, 51:346 354.
32. Power KG, Sharp DM: Keep taking the tablets? Inadequate controls for concurrent psychotropic medication in studies of psychological treatments for panic disorder [Letter]. J Psychopharmacol 1995, 9:71 72.
33. Klein DF: Preventing hung jurles about therapy studies. J Consult Clin Psychol 1996, 64:81 87.
34. McNally RJ: Methodological controversies in the treatment of panic disorder. J Consult Clin Psychol 1996, 64:88 91.
35. Jacobson NS, Hollon SD: Cognitive-behaviour therapy versus pharmacotherapy: now that the jury's returned its verdict, It's time to present the rest of the evidence. J Consult Clin Psychol 1996, 64:74 80.